Levetiracetam Tablet
Product Images NDC 76282-247

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 76282-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring with various functional groups attached, consistent with the generic name Levetiracetam.*

FDA Label Image

Levetiracetam 750 mg Tablets, Usp (Levetiracetam Tablets 10)

Label for Levetiracetam Tablets, USP 750 mg oral tablets by Exelan Pharmaceuticals, Inc. The label states the product is prescription only and contains 120 tablets. It includes storage instructions and notes for pharmacists on dispensing with a medication guide and a child-resistant container. Manufactured by InvaGen Pharmaceuticals, Inc.*

FDA Label Image

Fig 1 (Levetiracetam Tablets 2)

A bar chart comparing percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows percentage of patients from 0% to 45%. The chart indicates higher patient percentages for Levetiracetam groups than placebo.*

FDA Label Image

Fig 2 (Levetiracetam Tablets 3)

A bar chart showing the percentage of patients responding to placebo and two doses of Levetiracetam (1000 mg/day and 2000 mg/day). The y-axis represents the percentage of patients, and the x-axis lists Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day groups with sample sizes. Response rates increase with dose, from 6.3% for placebo to 20.8% and 35.2% for the Levetiracetam groups.*

FDA Label Image

Fig 3 (Levetiracetam Tablets 4)

A bar graph comparing the percentage of patients responding to Placebo versus Levetiracetam 3000 mg/day. The vertical axis shows percentage of patients, with Placebo at 14.4% (N=104) and Levetiracetam at 39.4% (N=180), illustrating a higher response rate for Levetiracetam.*

FDA Label Image

Fig 4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients for placebo and levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the levetiracetam group (N=101) shows 44.6% of patients, with an asterisk indicating statistical significance.*

FDA Label Image

Fig 6 (Levetiracetam Tablets 7)

A bar graph comparing the percentage of patients for placebo and Levetiracetam groups. The y-axis shows the percentage of patients from 0% to 100%. The placebo group, with 84 patients, shows 45.2%, while the Levetiracetam group, with 79 patients, shows 72.2%. An asterisk marks the Levetiracetam bar.*

FDA Label Image

Levetiracetam 250 mg Tablets, Usp (Levetiracetam Tablets 8)

Levetiracetam Tablets USP 250 mg oral tablet packaging label from Exelan Pharmaceuticals, Inc. The label indicates 120 tablets per container, includes storage instructions, pharmacist dispensing guidelines, and manufacturer information for Exelan Pharmaceuticals, Inc. and InvaGen Pharmaceuticals, Inc. The NDC number is 76282-246-12.*

FDA Label Image

Levetiracetam 500 mg Tablets, Usp (Levetiracetam Tablets 9)

Levetiracetam Tablets USP 500 mg oral tablets label for a bottle containing 120 tablets. Label shows the NDC 76282-247-12 and is manufactured for Exelan Pharmaceuticals, Inc., with manufacturing by InvaGen Pharmaceuticals, Inc. Storage and dispensing instructions are included along with a barcode and QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.